Abstract: Ramipril has recently been shown to have anti-atherogenic properties. However, the specific mechanisms underlying these effects remain unclear. The purpose of this study was to determine the effects of ramipril on induction of adhesion molecules in human umbilical vein endothelial cells (HUVECs) using high-glucose (HG) conditions and to investigate possible underlying molecular mechanisms. The effects of ramipril on expression of intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1 production, and ERK phosphorylation were examined in HG-induced HUVECs with inhibitors targeting the mitogen-activated protein kinase (MAPK) signaling pathway. HG induced the expression of the adhesion molecules ICAM-1 and VCAM-1. Pretreatment with ramipril drastically inhibited ICAM-1 and VCAM-1 production in a time-and dose-dependent manner. Moreover, upon investigating Vol. 20. No. 5. 2015 CELL. MOL. BIOL. LETT. 938 the effects of ramipril on the MAPK/extracellular signal-regulated kinase (ERK) signaling pathway, we found that ramipril completely inhibited HG-induced phosphorylation of ERK1/2. ERK inhibitors completely prevented the inhibitory effect of HG. This study demonstrated that ramipril reduces HG-stimulated induction of ICAM-1 and VCAM-1 expression via MAPK signaling, which may be useful for inhibition of atherosclerosis.
INTRODUCTION
Atherosclerosis is one of the major contributors to cardiovascular morbidity and mortality due to the development of heart diseases such as myocardial infarction [1] . It is well known that hyperlipidemia and inflammation are the underlying fundamental pathophysiologies of atherosclerosis. In addition, among various systemic diseases, patients with diabetes mellitus have an increased risk of developing atherosclerosis [2] . Specifically, patients with type 1 or type 2 diabetes mellitus have an up to 6-fold increased risk of atherosclerosis compared to nondiabetic patients with comparable risk factors. Vascular smooth muscle cells (SMCs) play an important role in the pathogenesis of atherosclerosis, especially in the formation of calcific crystals [3] . In the presence of high glucose concentrations, vascular endothelial cells (ECs) are at an increased risk of injury. Inflammatory injury and subsequent dysfunction of ECs stimulate the proliferation and migration of SMCs, which are key pathological features of atherosclerosis [4] . In addition, various cellular adhesion molecules are expressed on the surface of ECs, SMCs, and circulating leukocytes in response to various inflammatory stimuli such as lipids. The adhesion of leukocytes to ECs during atherosclerosis is also primarily mediated by cellular adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) [5] . Importantly, VCAM-1 is induced in response to inflammatory cytokines such as TNF-α [6] , indicating that VCAM-1 plays a dominant role in the development and progression of atherosclerotic lesions. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor [7] used to treat high blood pressure and congestive heart failure. Ramipril is metabolized to ramipril in the liver and kidneys, and recent studies have suggested that ACE inhibitors have many beneficial effects on vascular function, including reduction of cardiovascular risk in patients with advanced atherosclerosis or arterial hypertension [8] . In addition to their anti-hypertensive effects, ACE inhibitors have various beneficial effects including anti-inflammatory properties, increasing nitric oxide bioavailability in human vasculature, and reducing cardiovascular disease risk [9] . However, little is known about the underlying mechanisms of the anti-inflammatory and anti-atherogenic properties of ramipril.
In the present study, we investigated the effect of ramipril on the expression of adhesion molecules in endothelial cells under high glucose conditions. We also investigated possible mechanisms, focusing especially on the mitogen-activated protein kinase (MAPK) signaling pathway.
MATERIALS AND METHODS

Chemicals and antibodies
Ramipril was purchased from Handok Pharmaceuticals Co. Ltd. (Seoul, Korea). D-glucose was purchased from Sigma (St. Louis, MO, USA). The signal pathway inhibitors U0126, SP600125, and SB202190 were purchased from Calbiochem (La Jolla, CA, USA). Antibodies against ICAM-1, VCAM-1, and β-actin were purchased from Santa Cruz Biotechnology Inc. (Beverly, MA, USA). Antibodies against ERK and phospho-ERK were purchased from Cell Signaling Technology (Beverly, MA, USA). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG and goat anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA) were used as secondary antibodies.
Cell culture
HUVECs (human umbilical vein endothelial cells) were isolated from umbilical cord veins as previously reported [10] using collagenase treatment (Roche Diagnostics, Indianapolis, IN, USA). HUVECs were grown in medium (EGM)-2 (Clonetics, Walkersville, MD, USA) supplemented with EGM-2 SingleQuots (Clonetics), which contains recombinant epidermal growth factor (EGF), human fibroblast growth factor-basic (hFGF-B), vascular endothelial growth factor (VEGF), ascorbic acid, hydrocortisone, human recombinant insulin-like growth factor (R 3 -IGF-1), ascorbic acid, heparin, fetal bovine serum (FBS), gentamicin, and amphotericin-B. HUVECs were plated in 20 μg/ml collagen (BD Biosciences, San Jose, CA, USA) in 0.1 mM HCl-coated 75T flasks (BD Biosciences). HUVECs were used between passages 2 and 6, and were maintained at 37°C in a humidified atmosphere containing 5% CO 2 and 95% air.
RNA isolation and reverse transcription-polymerase chain reaction
The mRNA expression in the HUVECs was quantified using reverse transcription-polymerase chain reaction (RT-PCR) analysis, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA as the internal standard. The total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA), as described in the previous report [11] . Briefly, 1.5 μg of total RNA was reverse transcribed into cDNA, using the RevertAid First Strand cDNA Synthesis kit (Fermentas, EU), and then amplified using PCR with specific primers for ICAM-1 (forward, 5′-CAAGGG GAGGTCACC CG GAGGTG-3′ and reverse, 5′-CAA GGG AGG TCA CCC GCG AGC C-3′), VCAM-1 1 (forward, 5′-GATACAACCGTCTTGGTCAGCCC-3′ and reverse, 5′-CAGTTGAAG GATGCGGGAGTATATG-3′), and GAPDH (forward, 5′-TGGGGCAGCCCAG AACATCA-3′ and reverse, 5′-GCC GCC TGC TTC ACA CCT T-3′). The PCR conditions were as follows: denaturation at 94°C for 5 min and 35 cycles of amplification (94°C for 30 s, 55°C for 30 s, and 72°C for 30 s), followed by 10 min at 72°C. Equal amounts of the RT-PCR products were separated on a 1.5% agarose gel and stained with ethidium bromide.
Western blotting
Western blot analyses were performed as described previously [10, 12] . Briefly, after treatments, cells were washed with cold PBS (pH 7.4) and scraped in icecold lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 10% glycerol, 1% Triton-X, 1 mM Na 3 VO 4 ) containing a protease inhibitor cocktail (Sigma, St. Louis, MO, USA). The lysates were sonicated and centrifuged at 13,000 rpm for 20 min at 4°C and the supernatant was collected. For western blotting, equal amounts of protein were run on 8-10% sodium dodecyl sulfate (SDS)-polyacrylamide gels, which were then transferred to nitrocellulose membranes (Amersham-Pharmacia Biotech, Piscataway, NJ, USA), blocked with blocking buffer (5% non-fat dry milk/1% Tween 20; in 20 mM TBS, pH 7.6) for 1 h at room temperature, and finally incubated with monoclonal or polyclonal primary antibodies (1:1000) in blocking buffer overnight at 4°C. After the blots were incubated with the appropriate anti-mouse or anti-rabbit secondary antibody horseradish peroxidase (HRP)-conjugated secondary antibody (1:3000), they were detected by chemiluminescence (Thermo Scientific, Rockford, IL, USA) as described previously [13] . Protein expression levels were determined using an LAS-3000 SYSTEM (Fuji Photo Film, Japan). Incubation with a mouse monoclonal β-actin antibody (1:2000) was used as an equal loading control.
Statistical analysis
Data are shown as the mean ± standard deviation (SD) of at least 3 independent samples. Data were analyzed using Student's t-test for unpaired samples between two groups or by analysis of variance (ANOVA) followed by Dunnett's test for multiple comparisons. Values of p < 0.05 were considered significant.
RESULTS
Effect of glucose on the production of adhesion molecules
To examine whether glucose induces expression of ICAM-1 and VCAM-1 in HUVECs, we cultured HUVECs under normal glucose (5.5 mM/l) and high glucose (HG, 25 mM/l and 33 mM/l) conditions for 24 h as previously described [10] . Immunoblot analysis revealed that stimulation with glucose significantly enhanced the production of ICAM-1 and VCAM-1 compared with the osmotic control with mannitol (20 mM) in HUVECs (Figs. 1A and 1B) . 
Effect of ramipril on HG-induced adhesion molecules
To investigate whether ramipril inhibits the expression of adhesion molecules induced by HG levels, we pretreated HUVECs with ramipril at the indicated concentrations for 24 h and then stimulated the cells with 33 mM glucose for 24 h. Ramipril inhibited the HG-induced increase in ICAM-1 and VCAM-1 mRNA ( Fig. 2A and 2B ) in a time-dependent manner and protein expression in a timeand dose-dependent manner (Fig. 3A, 3B, 3C and 3D) . Fig. 3 . Effect of ramipril on HG-induced ICAM-1 (A, C) and VCAM-1 (B, D) protein expression in HUVECs. A, B -HUVECs were pretreated with ramipril at a concentration of 30 μM for the indicated time (0-24 h) followed by treatment with glucose at a concentration of 33 mM for 24 h. *p < 0.05; **p < 0.01 for vs. 0 h. C, D -HUVECs were pretreated with ramipril at concentrations of 1-30 μM for 12 h, followed by treatment with glucose at a concentration of 33 mM for 24 h. Protein levels were determined by Western blot analysis. Control (C). *p < 0.05; **p < 0.01 vs. Vehicle (Veh).
Effects of U0126, SP600125, and SB202190 on HG-stimulated enhancement of adhesion molecules
To determine whether the ERK, JNK, or p38 MAPK pathways are involved in the HG-induced expression of ICAM-1 and VCAM-1, HUVECs were pretreated with U0126 (an inhibitor of ERK), SP600125 (an inhibitor of JNK), and SB202190 (an inhibitor of p38 MAPK) for 30 min and then stimulated with HG (33 mM) and/or ramipril (30 µM) for 24 h. U0126 (10 µM) completely inhibited the effect of HG on ICAM-1 and VCAM-1 ( Fig. 4A and 4B) . However, SP600125 and SB202190 did not affect the effect of HG on ICAM-1. 
Effect of ramipril on HG-induced phosphorylation of extracellular signalregulated kinase
After we identified the involvement of the ERK pathway, we analyzed the ERK phosphorylation levels to determine whether ramipril played a role in that activation under HG conditions. First, HUVECs were pretreated with 1-30 μM ramipril for 30 min and then stimulated with 33 mM glucose for 1 h. The HG-induced increase in pERK phosphorylation was inhibited by ramipril in a concentrationdependent manner (Fig. 5) . Fig. 5 . Effect of ramipril on HG-induced ERK phosphorylation in HUVECs. Cells were pretreated with ramipril at the indicated concentrations (1, 3, 10, and 30 μM) for 30 min, and then treated under HG conditions (33 mM) for 1 h. ERK activity (pERK) was determined by Western blot analysis. Equal loading of the gel was confirmed by probing blots for total ERK. *p < 0.05; **p < 0.01 for vs. Vehicle (Veh). Control (C).
DISCUSSION
In this study, we investigated whether ramipril has an inhibitory effect on HG-induced expression of adhesion molecules in HUVECs and looked into possible mechanisms of action. To the best of our knowledge, this is the first report showing that ramipril reduces HG-induced ICAM-1 and VCAM-1 production via the MAPK signaling pathway. Chronic inflammation is crucial in the pathogenesis of atherosclerosis. Such chronic inflammation is stimulated by lipids, especially low-density lipoproteins, and leukocytes [14] . Initiation of atherosclerosis involves activation of vascular endothelium with expression of various adhesion molecules including e-selectin, p-selectin, ICAM-1, and VCAM-1 [15] . In turn, expression of adhesion molecules leads to recruitment and adherence of leukocytes to the vascular endothelium, as well as their transmigration into the intima. Atherosclerosis is associated with increased morbidity and mortality. Interestingly, it is well documented that the risk of atherosclerosis is increased in diabetic patients, who are prone to both macro-and micro-vascular complications, compared with non-diabetic individuals [16] . Likewise, in patients with type 2 diabetes mellitus, low-density lipoprotein levels are often increased while high-density lipoprotein levels are decreased, a trend that is associated with an increased risk of atherosclerosis. In addition to abnormal lipid profiles, hypertension is also often present in patients with diabetes mellitus. Based on these observations, the anti-inflammatory, endothelium-protecting, and anti-atherogenic properties of ramipril may be especially relevant not only to individuals with hypertension but also to those with diabetes [17] [18] [19] . In the present study, we found that the adhesion molecules ICAM-1 and VCAM-1 are significantly overexpressed in HUVECs under HG conditions. Importantly, when we pre-treated HUVECs with various concentrations of ramipril before exposure to HG conditions, we found that ramipril significantly suppressed the overexpression of adhesion molecules. These results suggested an anti-adhesion and inhibitory effect of ramipril on the pathogenesis of atherosclerosis under HG conditions. We also employed various inhibitors of the MAPK pathway, which is part of the phosphorylation cascade that includes ERK, JNK, and p38 MAPK [20] . Among the three inhibitors, U0126 significantly inhibited the overexpression of adhesion molecules under the HG condition in HUVECs, whereas the others did not. This result suggests that the ERK pathway was involved in this inhibitory effect. Then, we investigated the effect of ramipril on ERK phosphorylation under HG conditions and found that ramipril significantly suppressed it. These results indicate that ramipril acts through the ERK pathway, one of the MAPK pathways, inhibiting the overexpression of adhesion molecules in HUVECs under HG conditions. It has been reported that the ERK pathway plays a major role in regulating cell growth, survival, and differentiation, whereas JNK and p38 pathways are activated by stress signals, leading to cellular apoptosis [21, 22] . However, the results shown in Fig. 5 indicate that the most significant effect of ramipril on ERK phosphorylation happened in the range of 3 to 10 μM. The effect of ramipril at 30 μM was greatly diminished. However, the author used 30 μM ramipril for the time-dependent response of HG-induced ICAM-1 and VCAM-1 expression in HUVECs (Fig. 3) . The discrepancy of the results between ERK phosphorylation and VCAM-1/ICAM-1 expression might be caused by different ramipril and HG treatment time points. In addition, expression of adhesion molecules is critically dependent on intracytoplasmic activation of NF-kappa B [23] . The effect of ramipril on NF-kappa B may be associated with HG, and this needs to be elucidated. The results of the present study identified anti-atherogenic properties of ramipril under HG conditions facilitated by ERK. Specifically, ramipril significantly suppressed overexpression of the vascular adhesion molecules ICAM-1 and VCAM-1 in HUVECs under HG conditions. Based on these data, we speculate that systemic administration of ramipril may be helpful for prevention of atherosclerosis as well as treatment of hypertension in patients with diabetes mellitus. However, our study is limited for the use of vein endothelial cells in atherosclerotic study.
